Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
None
Efficacy of Olanzapine Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly

  • 0 views
  • 04 Apr, 2021
  • 1 location
None
Cisplatin Disposition and Kidney Injury

This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of …

  • 0 views
  • 08 Oct, 2021
  • 2 locations
None
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron

biomarker analysis
doxorubicin
cyclophosphamide
trastuzumab
cancer
  • 6 views
  • 11 Nov, 2021
  • 16 locations
None
Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery

Postoperative nausea and vomiting (PONV) are common in patients, especially in patients at high risk. PONV may result in prolonged hospital stay and threaten patients' life. Because the etiology of PONV is very complex, there is an increasing focus on combining antiemetics from different classes for PONV prophylaxis. Fosaprepitant is …

  • 0 views
  • 21 Nov, 2021
  • 1 location
None
Oral Akynzeo vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

MyRisk: Efficacy and safety evaluation of oral Akynzeo in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study. Antiemetic guidelines recommendations are based on the emetogenic potential of the chemotherapy. Chemotherapy (CT) agents are divided in Highly, Moderately, Low and …

  • 3 views
  • 25 Sep, 2021
  • 5 locations
None
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

This is a multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in

palonosetron
absolute neutrophil count
antiemetics
netupitant
cancer
  • 7 views
  • 24 Jan, 2021
  • 1 location
None
AKY15-HK-301_NEPA Study

response to conditions that affect the gut and the vomiting center, which is an area in the brain. Netupitant and palonosetron are drugs that are thought to block the activation of certain types of

immunostimulant
adriamycin
cyclophosphamide
cancer treatment
adjuvant chemotherapy
  • 0 views
  • 07 Aug, 2021
  • 1 location
None
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma

This is an open-label, multi-center, prospective, single arm phase 2 trial of the combination of bendamustine and rituximab in patients with PTLD, monomorphic cluster of differentiation antigen 20(CD20) positive DLBCL. The investigators want to investigate the efficacy and safety of the combination of bendamustine and rituximab in patients with previously …

renal function
bendamustine
rituximab
platelet count
measurable disease
  • 11 views
  • 21 Jan, 2021
None
Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

This is an open label study for any patients with a bile duct cancer or gallbladder cancer, who will be treated with gemcitabine and cisplatin chemotherapy (the ABC02 regime). Patients recruited onto this study will have a reduction of their hydration time and be given Akynzeo as an anti-sickness drug, …

renal function
cholangiocarcinoma
gemcitabine
carcinoma
cancer
  • 4 views
  • 13 Mar, 2021
  • 1 location